Concourse Financial Group Securities, Inc. Larimar Therapeutics, Inc. Transaction History
Concourse Financial Group Securities, Inc.
- $0
- Q2 2025
Number of Shares
0
Previous 0
NaN%
Holding current value
$0
Previous $0
NaN%
% of portfolio
100.0%
Previous 100.0%
Shares
22 transactions
Others Institutions Holding LRMR
# of Institutions
133Shares Held
67.9MCall Options Held
4.83MPut Options Held
83.7K-
Deerfield Management Company, L.P. (Series C) New York, NY21.2MShares$77.1 Million1.41% of portfolio
-
Ra Capital Management, L.P. Boston, MA6.05MShares$21.9 Million0.38% of portfolio
-
Blue Owl Capital Holdings LP New York, NY4.93MShares$17.9 Million7.71% of portfolio
-
Opaleye Management Inc. Boston, MA4.11MShares$14.9 Million2.84% of portfolio
-
Israel Englander Millennium Management LLC | New York, Ny3.66MShares$13.3 Million0.01% of portfolio
About Larimar Therapeutics, Inc.
- Ticker LRMR
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 43,269,200
- Market Cap $157M
- Description
- Larimar Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing treatments for rare diseases using its novel cell penetrating peptide technology platform. Its lead product candidate is CTI-1601, which is in Phase 1 clinical trial for the treatment of Friedreich's ataxia, a rare, progressive, and fatal genetic disease. T...